Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study | Zendy

Nan Chen | Zendy; Xin Wu | Zendy; Xiaoqiang Ding | Zendy; Changlin Mei | Zendy; Ping Fu | Zendy; Gengru Jiang | Zendy; Xiaogang Li | Zendy; J. Chen | Zendy; B. Liu | Zendy; Yun Kyung La | Zendy; Fan Fan Hou | Zendy; Zhaohui Ni | Zendy; Jing Fu | Zendy; Changying Xing | Zendy; Xiaoli Yu | Zendy; Chongan Huang | Zendy; Li Zuo | Zendy; Lei Wang | Zendy; John Hunter | Zendy; Michael C. Dillon | Zendy; Melissa A. Plone | Zendy; John F. Neylan | Zendy

Open Access

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study

Author(s) -

Nan Chen,

Xin Wu,

Xiaoqiang Ding,

Changlin Mei,

Ping Fu,

Gengru Jiang,

Xiaogang Li,

J. Chen,

B. Liu,

Yun Kyung La,

Fan Fan Hou,

Zhaohui Ni,

Jing Fu,

Changying Xing,

Xiaoli Yu,

Chongan Huang,

Li Zuo,

Lei Wang,

John Hunter,

Michael C. Dillon,

Melissa A. Plone,

John F. Neylan

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gft232

Subject(s) - sevelamer , medicine , phosphate binder , hyperphosphatemia , placebo , kidney disease , dialysis , hemodialysis , urology , adverse effect , gastroenterology , surgery , pathology , alternative medicine

Hyperphosphataemia in patients with advanced chronic kidney disease (CKD) is associated with adverse outcomes, including vascular calcification and higher mortality rates. While phosphate lowering is an integral aspect of CKD management, the efficacy and safety of phosphate binders in a contemporary cohort of Chinese haemodialysis patients (who have different genetics and dietary patterns than other populations) has not been previously described. Moreover, sparse data are available on strategies for optimal dose titration when transitioning from a calcium-based to a polymer-based phosphate binder.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research